VIT will enjoy likely enjoy increased rev this year, and will be profitable. They will also have the combination of a professional CEO and have a highly accomplished Chair.
The C4C drama is just that. The new platform will actually be better and is on track. VIT still maintains more presence in pharmacies and practitioners than any of the competitors. Canview will not be turned off.
Cleary market hysteria. Hard to see how this stock compares to the likes of Althea or ECS.
I’m loving the bargain stock and are buying up. DYOR
VIT will enjoy likely enjoy increased rev this year, and will be...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
